Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

Sharon B Wigal, Scott H Kollins, Ann C Childress, Ben Adeyi, Sharon B Wigal, Scott H Kollins, Ann C Childress, Ben Adeyi

Abstract

Background: Efficacy and safety profiles by sex and age (6-9 vs 10-12 years) and magnitude and duration of effect by effect size overall and across the day of lisdexamfetamine dimesylate (LDX) vs placebo were assessed.

Methods: This study enrolled children (6-12 years) with attention-deficit/hyperactivity disorder (ADHD) in an open-label dose optimization with LDX (30-70 mg/d) followed by a randomized, double-blind, placebo-controlled, 2-way crossover phase. Post hoc analyses assessed interaction between sex or age and treatment and assessed effect sizes for Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) and Permanent Product Measure of Performance (PERMP) scales and ADHD Rating Scale IV measures. No corrections for multiple testing were applied on time points and subgroup statistical comparisons.

Results: 129 participants enrolled; 117 randomized. Both sexes showed improvement on all assessments at postdose time points; females showed less impairment than males for SKAMP and PERMP scores in treatment and placebo groups at nearly all times. Both age groups improved on all assessments at postdose time points. Children 10-12 years had less impairment in SKAMP ratings than those 6-9 years. Treatment-by-sex interactions were observed at time points for SKAMP-D, SKAMP total, and PERMP scores; no consistent pattern across scales or time points was observed. LDX demonstrated significant improvement vs placebo, by effect size, on SKAMP-D from 1.5-13 hours postdose. The overall LS mean (SE) SKAMP-D effect size was -1.73 (0.18). In the dose-optimization phase, common (≥2%) treatment-emergent adverse events (TEAEs) in males were upper abdominal pain, headache, affect lability, initial insomnia, and insomnia; in females were nausea and decreased weight. During the crossover phase for those taking LDX, higher incidence (≥2% greater) was observed in males for upper abdominal pain and insomnia and in females for nausea and headache. Overall incidence of TEAEs in age groups was similar.

Conclusion: Apparent differences in impairment level between sex and age groups were noted. However, these results support the efficacy of LDX from 1.5 hours to 13 hours postdose in boys and girls with medium to large effect sizes across the day with some variability in TEAE incidence by sex.

Trial registration number: ClinicalTrials.gov Identifier: NCT00500149.

Figures

Figure 1
Figure 1
Study design. Twelve participants discontinued prior to randomization; 4 participants discontinued during the crossover period; 2 participants discontinued after the crossover phase; 9 participants discontinued because of AEs; no participants discontinued because of lack of efficacy.
Figure 2
Figure 2
Postdose LS Mean (SE) SKAMP-D, SKAMP-A, and Total Scores by Time and Sex. Lower SKAMP scores indicate improvement.
Figure 3
Figure 3
Postdose LS Mean (SE) PERMP-A and PERMP-C Scores by Time and Sex. Higher PERMP subscale scores are indicative of improvement.
Figure 4
Figure 4
Postdose LS Mean (SE) SKAMP-D, SKAMP-A, and Total Scores by Time and Age. Lower SKAMP scores indicate improvement.
Figure 5
Figure 5
Postdose LS Mean (SE) PERMP-A and PERMP-C Scores by Time and Age. Higher PERMP subscale scores are indicative of improvement.

References

    1. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M. The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642–657. doi: 10.1097/01.chi.0000215326.51175.eb.
    1. Stein MA, Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contemp Pediatr. 2003;20:83–110.
    1. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008;9:1565–1574. doi: 10.1517/14656566.9.9.1565.
    1. Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother. 2007;8:745–758. doi: 10.1517/14656566.8.6.745.
    1. Stein MA. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care. 2004;10(suppl):S89–S98.
    1. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study) Pediatrics. 2004;113:e206–e216. doi: 10.1542/peds.113.3.e206.
    1. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317–327. doi: 10.2147/NDT.S9749.
    1. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450–463. doi: 10.1016/S0149-2918(07)80083-X.
    1. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970–976. doi: 10.1016/j.biopsych.2007.04.015.
    1. Wigal SB, Kollins SH, Childress AC, Squires L. for the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
    1. Gray JR, Kagan J. The challenge of predicting which children with ADHD respond positively to methylphenidate. J Applied Dev Psychol. 2000;21:471–489. doi: 10.1016/S0193-3973(00)00050-2.
    1. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088–1096. doi: 10.1001/archpsyc.56.12.1088.
    1. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71:540–552. doi: 10.1037/0022-006X.71.3.540.
    1. Sonuga-Barke EJS, Coghill D, Markowitz JS, Swanson JM, Vandenberghe M, Hatch SJ. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry. 2007;46:701–710. doi: 10.1097/chi.0b013e31804659f1.
    1. Rucklidge JJ. Gender differences in ADHD: implications for psychosocial treatments. Expert Rev Neurother. 2008;8:643–655. doi: 10.1586/14737175.8.4.643.
    1. Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5:143–154. doi: 10.1177/108705470200500302.
    1. Abikoff HB, Jensen PS, Arnold LL, Hoza B, Hechtman L, Pollack S, Martin D, Alvir J, March JS, Hinshaw S, Vitiello B, Newcorn J, Greiner A, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Kraemer H, Pelham WE Jr, Severe JB, Swanson JM, Wells K, Wigal T. Observed classroom behavior of children with ADHD: relationship to gender and comorbidity. J Abnorm Child Psychol. 2002;30:349–359. doi: 10.1023/A:1015713807297.
    1. Quinn P, Wigal S. Perceptions of girls and ADHD: results from a national survey. MedGenMed. 2004;6:2.
    1. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1284–1293. doi: 10.1097/01.chi.0000235077.32661.61.
    1. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180–187. doi: 10.1097/00004583-200102000-00012.
    1. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–1303. doi: 10.1097/01.chi.0000235082.63156.27.
    1. Wigal SB, Gupta S, Greenhill L, Posner K, Lerner M, Steinhoff K, Wigal T, Kapelinski A, Martinez J, Modi NB, Stehli A, Swanson J. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17:153–164. doi: 10.1089/cap.2007.0043.
    1. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404. doi: 10.1542/peds.112.5.e404.
    1. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P&T. 2009;34:678–694.
    1. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34:47–53.
    1. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10:92–111. doi: 10.1177/1087054705286049.
    1. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
    1. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med. 2002;21:2131–2144. doi: 10.1002/sim.1205.
    1. McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont) 2009;6:21–29.
    1. Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull. 1992;112:155–159. doi: 10.1037/0033-2909.112.1.155.
    1. Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav. 1999;64:803–812. doi: 10.1016/S0091-3057(99)00168-9.
    1. Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59:966–974. doi: 10.1016/j.biopsych.2006.01.008.
    1. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816–818. doi: 10.1176/appi.ajp.157.5.816.
    1. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol. 1995;23:729–749. doi: 10.1007/BF01447474.
    1. Todd RD, Huang H, Todorov AA, Neuman RJ, Reiersen AM, Henderson CA, Reich WC. Predictors of stability of attention-deficit/hyperactivity disorder subtypes from childhood to young adulthood. J Am Acad Child Adolesc Psychiatry. 2008;47:76–85. doi: 10.1097/chi.0b013e31815a6aca.
    1. Faraone S, Schreckengost J. Lisdexamfetamine dimesylate effect size in children with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry's 54th Annual Meeting; October 23-28, 2007, Boston, MA.
    1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237–248. doi: 10.1016/S0140-6736(05)66915-2.
    1. Smith BH, Pelham WE, Gnagy E, Yudell RS. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry. 1998;37:314–321. doi: 10.1097/00004583-199803000-00017.
    1. McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673–683. doi: 10.1097/01.CHI.0000046863.56865.FE.
    1. Pierce D, Dixon CM, Wigal SB, McGough JJ. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18:355–364. doi: 10.1089/cap.2007.0148.
    1. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin. 2008;24:33–40.
    1. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:258–266. doi: 10.1542/peds.110.2.258.
    1. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1406–1414. doi: 10.1097/01.chi.0000138351.98604.92.
    1. Arnold LE. Sex differences in ADHD: conference summary. J Abnorm Child Psychol. 1996;24:555–569. doi: 10.1007/BF01670100.
    1. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28:265–273. doi: 10.1097/DBP.0b013e31811ff87d.
    1. Werry JS, Aman MG, Diamond E. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry. 1980;21:27–35. doi: 10.1111/j.1469-7610.1980.tb00013.x.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren